Next Gen Oncology Products
Using our broadly versatile SnAP technology both of our programs combine clinically validated pieces in a unique way to create a ‘whole greater than the sum of its parts’ … for truly targeted delivery of potent proven payloads resulting in tumor killing function.
MDT-01 "MeARC"
Meditope-enabled Antibody Radioisotope Conjugate combines the power of radiation therapy directed via the high tumor specificity of antibodies:
-
First-in-class antibody directed radiopharma drug for multiple myeloma
-
Shortwave radioisotope conjugated with SnAP Technology
Resulting in:
-
Potential for treatment of patients with treatment resistant and/or reoccurrences including immune exhausted cases
-
Potent shortwave isotope delivered directly to cancer cells lowering off target toxicity
-
Optional conjugation prior to administration may reduce toxin decay adding to drug potency
MDT-02 "MeKine"
The proven power of cytokines combined with high tumor specificity of antibodies:
-
"Masked"/deactivated cytokine (IL-2)
-
Fused to antibody via protease cleavable linkers
Resulting in:
-
Potent and specific tumor cell killing
-
Validated tumor-associated antigen target provides further selectivity
-
Improved therapeutic window
